Streetbeat News

Regulatory

BGNE

BeiGene announced that its Phase 3 RATIONALE 315 trial met primary endpoints for tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer. The data showed 56.2% of patients achieved major pathological response, versus 15.0% with neoadjuvant chemotherapy alone. Also, 40.7% of patients achieved the key secondary endpoint of pathological complete response, compared to 5.7% with neoadjuvant chemotherapy alone.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:05 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlighted two studies demonstrating the positive financial impact of INPEFA (sotagliflozin), recently approved by the FDA for heart failure treatment. The studies, presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting, showed that while INPEFA increased pharmacy costs, it reduced medical costs due to lower readmission rates and fewer emergency department visits. The studies also concluded that INPEFA is a cost-effective treatment for heart failure among patients with type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:03 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained event-free survival and promising overall survival trends with three cycles of Opdivo in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer. The results showed a greater reduction in the risk of disease recurrence, progression or death than chemotherapy alone, regardless of PD-L1 expression levels. The results will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:51 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced results from the Phase 3 CheckMate -901 trial, where Opdivo in combination with cisplatin-based chemotherapy demonstrated significant improvements in overall survival and progression-free survival for patients with unresectable or metastatic urothelial carcinoma. The treatment reduced the risk of death by 22% and showed a tolerable safety profile. The data will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:49 pm

EIS

SPY

USO

VGK

Russia and the UAE have requested an urgent meeting of the UN Security Council following a strike on a hospital in Gaza, according to Reuters citing Tass. The news may impact the performance of certain ETFs.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:43 pm

BMY

The Phase 3 Checkmate -77T trial of Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo showed a 42% reduction in the risk of disease recurrence, progression or death in patients with resectable non-small cell lung cancer. The data from the trial will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:27 pm

BIDU

Baidu, Inc. (NASDAQ:BIDU) shares dropped despite unveiling its Ernie 4.0 AI model. The decline is attributed to potential U.S.-China tensions following the U.S. announcement to halt shipments of advanced AI chips to China. The move is aimed at curtailing China's development of AI technologies over concerns of military use. Baidu, which has been advancing its AI goals, may be significantly impacted by these restrictions.

Portfolio Pulse from Ryan Gustafson

October 17, 2023 | 7:03 pm

EIS

SPY

Mahmoud Abbas, the President of the Palestinian Authority, has cancelled his planned meeting with US President Joe Biden. No specific reasons were given for the cancellation.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:59 pm

USB

US Bancorp shares are trading higher following the announcement that the Federal Reserve will not require the company to meet Category II requirements by Dec. 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:53 pm

VRTX

Health Canada has granted market authorization for TRIKAFTA, a drug for children aged 2 to 5 years with at least one F508del mutation in cystic fibrosis. The drug is produced by Vertex Pharmaceuticals (VRTX).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:53 pm